Omega-3 (DHA/EPA): Cardiovascular Health, Cognition, Inflammation & Brain Development — Evidence Review
⚡ 60-Second Summary
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 polyunsaturated fatty acids. EPA (20:5n-3) is primarily anti-inflammatory — competing with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing proinflammatory prostaglandins and leukotrienes. DHA (22:6n-3) is the dominant structural fatty acid of neuronal membranes, photoreceptors, and the heart. Both are found in fatty fish, fish oil, and algal oil.
Best-evidenced uses: Triglyceride reduction (strong, FDA-approved at 4 g/day prescription for hypertriglyceridemia); ASCVD outcomes (REDUCE-IT trial: icosapentaenoic acid/EPA reduced cardiovascular events 25% vs. placebo in statin-treated high-risk patients); anti-inflammatory effects; brain development and cognitive support; depression adjunct therapy; dry eye disease; pregnancy (DHA for fetal brain development).
Practical note: EPA and DHA have partially different effects — EPA is more anti-inflammatory and cardiovascular; DHA is more neurological and structural. Most fish oil provides both in roughly 2:1 to 3:2 EPA:DHA ratio. For cardiovascular events (REDUCE-IT), pure high-dose EPA (Vascepa, icosapentaenoic acid) at 4 g/day is the FDA-approved cardiovascular indication. For general health, combined EPA+DHA from high-quality fish oil or algal oil is appropriate.
What is Omega-3 (DHA/EPA)?
EPA's anti-inflammatory mechanism: EPA competes with arachidonic acid (AA) for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, reducing proinflammatory prostaglandin E2, thromboxane A2, and leukotriene B4 production. EPA also generates specialized pro-resolving mediators (SPMs: resolvins E1, E2; protectins). DHA generates resolvins D1–D6 and protectins/neuroprotectins. SPMs are distinct from anti-inflammatory compounds — they actively resolve inflammation rather than just suppressing it.
Omega-3 research spans 40+ years and over 10,000 clinical studies. Key milestones: 1980 — Bang and Dyerberg's Greenland Eskimo studies linking omega-3 intake to low cardiovascular disease; 1997 — GISSI-Prevenzione trial (1 g/day fish oil, 11,000 MI survivors: 20% reduction in total mortality); 2018 — REDUCE-IT trial (4 g/day EPA/Vascepa: 25% cardiovascular event reduction, 35% cardiovascular death reduction in high-risk patients on statins).
Evidence-based benefits
1. Triglyceride reduction
FDA-approved omega-3 at 4 g/day reduces triglycerides by 20–50% — highly effective for hypertriglyceridemia. Effect is dose-dependent; 1–2 g/day produces 10–20% reduction. Mechanism involves reduced hepatic VLDL-triglyceride secretion.
2. Cardiovascular outcomes (EPA focus)
REDUCE-IT (n=8,179): icosapentaenoic acid 4 g/day reduced major cardiovascular events by 25% and cardiovascular death by 35% vs. mineral oil placebo in high-risk patients on statins with elevated triglycerides. This is landmark evidence for pure EPA.
3. Anti-inflammatory and rheumatoid arthritis
Meta-analyses show omega-3 (3 g/day, 3+ months) reduces RA morning stiffness, tender joints, and NSAID requirements. Inflammatory marker (IL-1, IL-6, TNF-alpha) reduction is consistent.
4. Brain development and cognitive function
DHA is essential for fetal brain and retinal development. Maternal DHA supplementation improves infant cognitive and visual outcomes. In adults, omega-3 supplementation shows modest benefits for depression, ADHD, and age-related cognitive decline.
Supplement forms compared
| Form | Typical dose / Bioavailability | Best for | Notes |
|---|---|---|---|
| Fish oil (EPA+DHA) | 1–4 g combined EPA+DHA/day | General health, anti-inflammatory, CV | Most common form. Quality varies; look for USP verified or IFOS certified. Store cold. |
| Triglyceride-form fish oil | 1–4 g/day | Better bioavailability than ethyl ester | Natural triglyceride form absorbs ~70% better than ethyl ester (standard form). |
| Ethyl ester fish oil (Lovaza, Omacor) | 1–4 g/day | Prescription-grade for hypertriglyceridemia | FDA-approved at 4 g/day for Rx use; ethyl ester form slightly less bioavailable than TG form. |
| Icosapentaenoic acid / EPA only (Vascepa) | 4 g/day (prescription) | Cardiovascular event reduction in high-risk patients | FDA-approved for CV risk reduction in high-risk statin patients with elevated TG. |
| Algal oil (DHA dominant) | 200–600 mg DHA/day | Vegetarian/vegan; brain, pregnancy | Same DHA as fish oil; fish get DHA from algae; no fish-taste/contaminant concerns. |
How much should you take?
- Cardiovascular health (general): 1–2 g/day combined EPA+DHA
- Hypertriglyceridemia: 3–4 g/day (prescription forms for FDA-approved indication)
- Cardiovascular event reduction (high-risk): 4 g/day EPA only (Vascepa, prescription)
- Anti-inflammatory/RA: 2.7–3 g EPA+DHA/day
- Pregnancy: 200–300 mg DHA/day minimum; higher if DHA-deficient
Take omega-3 with meals containing fat to optimize absorption. Keep fish oil refrigerated to prevent oxidation. Choose products with IFOS certification or USP verification. Enteric-coated capsules reduce fish-breath reflux. At high doses (>3 g/day), monitor for excessive bleeding and discuss with physician if on anticoagulants.
Safety and side effects
Common side effects
- Fish breath and reflux (very common; use enteric-coated, cold storage, take with meals)
- Mild GI upset, loose stools at high doses
- Antiplatelet effects at high doses (>3 g/day) — monitor if on blood thinners
- Possible LDL-C increase with ethyl ester fish oil at high doses (mitigated by triglyceride form or icosapentaenoic acid)
Serious risks
Omega-3 is very safe at typical doses. The main clinical concerns are antiplatelet effects at high doses (additive with warfarin and antiplatelet drugs) and occasional LDL-C increase with high-dose ethyl ester forms. Fish oil quality and oxidation are practical consumer concerns.
Drug and nutrient interactions
- Warfarin and anticoagulants — additive antiplatelet effects at >3 g/day; monitor INR
- Antiplatelet drugs (aspirin, clopidogrel) — additive effects; usually beneficial for cardiovascular patients but monitor perioperatively
- Orlistat — weight loss drug may reduce fat-soluble nutrient absorption including omega-3; take 2 hours apart
Check our free interaction checker for additional combinations.
Who might benefit — and who should use caution
| Most likely to benefit | Use with caution or seek guidance |
|---|---|
| People with elevated triglycerides (>200 mg/dL) seeking dietary or prescription-grade reduction | People with fish allergy — use algal DHA; EPA sources are more limited for vegans |
| High-risk cardiovascular patients on statins — discuss prescription EPA (Vascepa) with cardiologist | People scheduled for surgery — stop high-dose omega-3 7+ days before; antiplatelet effects |
| Pregnant and breastfeeding women — 200–300 mg DHA/day minimum for fetal brain development | Those expecting omega-3 to cure established cardiovascular disease — benefit is for prevention and risk reduction |
| People with rheumatoid arthritis or chronic inflammation |
Frequently asked questions
How much fish oil should I take?
It depends on your goal. For general health and anti-inflammation: 1–2 g combined EPA+DHA/day. For triglyceride reduction: 2–4 g/day. For the cardiovascular event reduction shown in REDUCE-IT (high-risk patients on statins): 4 g/day pure EPA (prescription Vascepa). Check the label for EPA+DHA content per serving — a '1000 mg fish oil capsule' typically provides only 300 mg combined EPA+DHA.
What is the difference between fish oil and krill oil?
Fish oil provides EPA and DHA as triglycerides or ethyl esters; krill oil provides EPA and DHA primarily as phospholipids (phosphatidylcholine-bound). Phospholipid-bound omega-3 has better brain uptake and may absorb better per mg, but krill oil provides less EPA+DHA per capsule at comparable cost. For equivalent EPA+DHA doses, fish oil is significantly more cost-effective.
Is algal oil as good as fish oil for omega-3?
Yes, for DHA — algal oil provides the same DHA molecule as fish oil (fish get their DHA from algae). Algal DHA is equivalent in bioavailability and function. The challenge is EPA: most algal oils are DHA-dominant with little EPA. Schizochytrium and other EPA-producing algae are emerging but less established. For DHA supplementation (pregnancy, cognitive health), algal oil is an excellent vegan equivalent.
What is REDUCE-IT and why does it matter?
REDUCE-IT was a 2018 landmark RCT (n=8,179) comparing icosapentaenoic acid (pure EPA, 4 g/day) to placebo in patients already on statins with elevated triglycerides and existing cardiovascular disease or diabetes. EPA reduced major cardiovascular events by 25% and cardiovascular death by 35% — more than statins alone. This led to FDA approval of Vascepa for cardiovascular risk reduction in this high-risk population. It established high-dose pure EPA as a cardiovascular drug, not just a triglyceride supplement.
Can omega-3 cause bleeding?
At typical doses (1–2 g/day), omega-3 rarely causes clinically meaningful bleeding. At higher doses (>3 g/day), the antiplatelet effects become clinically significant and can be additive with blood thinners. Stop high-dose omega-3 at least 7 days before surgery. Discuss with your physician if you take warfarin, aspirin, or other antiplatelet drugs and use high-dose omega-3.
Related ingredients
Krill Oil
Phospholipid-form EPA/DHA with smaller doses but possible brain uptake advantage.
Algal DHA
Vegan EPA/DHA source from the same algae that fish consume.
Astaxanthin
Often found with fish oil products; potent carotenoid antioxidant for eye, skin, and recovery.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.